shot-button
Subscription Subscription
Home > News > India News > Article > Serum Institute of India restarts manufacturing of COVID 19 vaccine Covishield

Serum Institute of India restarts manufacturing of COVID-19 vaccine Covishield

Updated on: 12 April,2023 05:10 PM IST  |  New Delhi
PTI |

He said the company already has six million booster doses of Covovax vaccine available and adults must take the booster shot

Serum Institute of India restarts manufacturing of COVID-19 vaccine Covishield

Representative image. Pic/Istock

Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.


He said the company already has six million booster doses of Covovax vaccine available and adults must take the booster shot.


Reacting to reports of COVID-19 vaccines shortage, he said manufacturers are ready but there has been no demand.


Also Read: Covid-19 cases rising as the infection moves towards endemic stage in India

"Just as a precaution, at risk we have done it so that people have a Covishield as a choice if they want it," Poonawalla told PTI on restarting of manufacturing of the vaccine.

The company had stopped manufacturing of Covishield in December 2021.

On Covovax which has been approved as a booster dose for 18-years and above, he said, "We have six million doses ready but the demand is exactly zero."
Covovax booster is now on the CoWin app, he said. 

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK